Who Supplies Rivaroxaban to India from SLOVENIA

Importing finished pharmaceutical formulations containing Rivaroxaban into India requires compliance with regulations set by the Central Drugs Standard Control Organisation (CDSCO). The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The registration process typically takes several months, depending on the completeness of the application and the workload of CDSCO. For formulations under HS Code 30049099, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing evidence of the product's safety and efficacy.

Imported pharmaceutical formulations containing Rivaroxaban must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure the product's shelf-life in India's climate. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the product. If a batch fails quality testing, it may be rejected, leading to potential delays or the need for re-exportation.

Between 2024 and 2026, CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and Slovenia have streamlined the import process, reducing registration timelines and facilitating smoother trade. These changes aim to balance the promotion of domestic industry with the need for essential imported medicines.

India imports finished Rivaroxaban formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be available from local producers. The market size for Rivaroxaban in India is substantial, driven by its use in treating conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Despite the presence of domestic manufacturers, imports remain essential to fulfill the diverse needs of the Indian market.

The import of finished pharmaceutical formulations under HS Code 30049099 is subject to a Basic Customs Duty (BCD) of 10%. An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable. A Countervailing Duty (CVD) of 6% is also imposed. The total duty amounts to 17.10%. Additionally, a Social Welfare Surcharge (SWS) of 10% applies. The Integrated Goods and Services Tax (IGST) is levied at 12%. These duties collectively contribute to the total landed cost of imported formulations.

India sources finished Rivaroxaban formulations from Slovenia due to the country's competitive advantages, including adherence to international quality standards and the availability of specialized dosage forms. Slovenia's pharmaceutical industry is known for its robust regulatory compliance and efficient manufacturing processes. While other suppliers like China, Germany, and the United States also export Rivaroxaban formulations to India, Slovenia's share remains significant due to these factors.

India imports finished Rivaroxaban formulations from Slovenia due to the country's adherence to international quality standards and the availability of specialized dosage forms not produced domestically. Slovenia's pharmaceutical industry is recognized for its efficient manufacturing processes and compliance with regulatory requirements, making it a reliable source for high-quality formulations.

Compared to other suppliers like China, Germany, and the United States, Slovenia offers competitive advantages in terms of quality, regulatory compliance, and reliability. While China may offer lower prices, Slovenia's products are often perceived as higher quality, with better adherence to international standards. Germany and the United States are also reputable sources but may have higher costs associated with their products. Slovenia's unique advantage lies in its balance of quality and cost-effectiveness.

Importing finished Rivaroxaban formulations from Slovenia involves certain risks, including potential supply chain disruptions, currency fluctuations, and regulatory changes. However, Slovenia's stable political and economic environment, along with its robust pharmaceutical industry, mitigate these risks. Past shortages have been minimal, and the supply chain has proven to be reliable.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP) to manage financial risk.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to optimize inventory and reduce costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

Implementing these strategies can enhance procurement efficiency and mitigate